WO2008091618A1 - Use of d-ribose to treat cardiac arrhythmias - Google Patents

Use of d-ribose to treat cardiac arrhythmias Download PDF

Info

Publication number
WO2008091618A1
WO2008091618A1 PCT/US2008/000845 US2008000845W WO2008091618A1 WO 2008091618 A1 WO2008091618 A1 WO 2008091618A1 US 2008000845 W US2008000845 W US 2008000845W WO 2008091618 A1 WO2008091618 A1 WO 2008091618A1
Authority
WO
WIPO (PCT)
Prior art keywords
ribose
grams
atrial fibrillation
doses
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/000845
Other languages
English (en)
French (fr)
Other versions
WO2008091618A8 (en
Inventor
James D. Herrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioenergy Inc
Original Assignee
Bioenergy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioenergy Inc filed Critical Bioenergy Inc
Priority to JP2010517230A priority Critical patent/JP5396387B2/ja
Priority to DE602008003411T priority patent/DE602008003411D1/de
Priority to BRPI0806231-5A priority patent/BRPI0806231A2/pt
Priority to AT08713225T priority patent/ATE487485T1/de
Priority to CA2674717A priority patent/CA2674717C/en
Priority to CN2008800029553A priority patent/CN101588807B/zh
Priority to EP08713225A priority patent/EP2120968B1/en
Publication of WO2008091618A1 publication Critical patent/WO2008091618A1/en
Anticipated expiration legal-status Critical
Publication of WO2008091618A8 publication Critical patent/WO2008091618A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • the heart like other muscles, is caused to contract by electrical stimulation by nerve fibres.
  • the normal electrical conduction system allows the nerve impluse that is generated by the sinoatrial node of the heart to be propagated to and stimulate the myocardium to contract in an orderly progression, resulting in an efficient heart beat.
  • the nerve impulses proceed in the normal functional manner, the heart is said to be eurhthymic.
  • the nerve impulses are reduced or non-uniform the heart is said to be arrhythmic.
  • Arrhythmias may be paroxysmal, that is, acute and short lasting, or chronic.
  • Extrasystole is generally an acute, recurrent event which can be caused by underlying heart disease, valve defects, or may be induced by triggers such as caffeine, nicotine or alcohol. Extrasystole can be felt as ' "palpitations" and although disturbing, is not, in itself dangerous. Therapy comprises treatment of an underlying heart condition and avoidance of triggers.
  • Tachycardia is an increased heart rate and can be caused by any trigger that raises the adrenaline levels, such as stress, exercise, strong emotion, caffeine or amphetamine. Heart rate returns to normal as the condition subsides.
  • a severe form of arrhythymia is paroxysmal tachycardia, in which the ventricles contract rapidly and for a prolonged time in the absence of triggers or after the trigger has subsided. The condition is difficult to treat and can be fatal, as the ventricles may pass into fibrillation, in which the blood pressure drops to zero and circulation is halted. Immediate intervention with a defibrillating machine is necessary to preserve life.
  • Atrial fibrillation is a less serious occurrence.
  • blood is not passed to the ventricles efficiently. Circulation is not generally impaired if the period of fibrillation is short; however, the stagnated pool of blood may clot and the clots may be passed to the pulmonary circulatory bed, the coronary arteries, the brain or other organs. It is estimated that sbout 2.2 million Americans suffer from atrial fibrillation and about 15% of strokes are related to this condition. Paroxysmal atrial fibrillation may have vague symptoms of unease during an attack or the subject may be completely unaware of the condition. Diagnosis is made by the absence of the P wave, representing depolarization of the atria, on EKG.
  • Atrial fibrillation may be treated with medications which slow the heart rate, "thinning" the blood with aspirin or warfarin to protect the patient from clotting, controlling the heart rate with beta blockers, calcium channel blockers or cardiac glycoside. Electrocardioversion may give persistent normalizing results.
  • D-ribose in low doses, treats atrial fibrillation and prevents its occurrence partially or completely.
  • Administration of five grams of D-ribose daily, taken as a single dose or divided into two doses is effective at preventing atrial fibrillation. More preferably, ten grams of D-ribose daily, divided into two to four doses is effective at preventing atrial fibrillation. Most preferably, the subject ingests 15 grams of D-ribose daily, divided into at least three doses. No more than five grams of D-ribose is ingested in one dose.
  • the D-ribose may be taken in a small amount of water, sprinkled on food, or ingested as a powder.
  • D-ribose to improve the function of skeletal and heart muscle has been documented.
  • United States Patent Number 6,159943 teaches that D- ribose can relieve the cramps and soreness in skeletal muscle caused by exercise.
  • Pending US Patent Application Serial Number 10/692,388 teaches that low doses of D-ribose can improve the cardiac function of patients suffering from congestive heart failure. While the use of D-ribose for improving the function of skeletal and cardiac muscle is now well known, before this invention nothing was known of the effect of D-ribose on nerve function. Not wishing to be bound by theory, Applicant speculates that the beneficial effect of D-ribose found in the following study may be due to improving the transmission of the nerve impulses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PCT/US2008/000845 2007-01-23 2008-01-23 Use of d-ribose to treat cardiac arrhythmias Ceased WO2008091618A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2010517230A JP5396387B2 (ja) 2007-01-23 2008-01-23 心臓不整脈を治療するためのｄ−リボースの用途
DE602008003411T DE602008003411D1 (de) 2007-01-23 2008-01-23 Verwendung von d-ribose zur behandlung von vorhofflimmern
BRPI0806231-5A BRPI0806231A2 (pt) 2007-01-23 2008-01-23 método para utilização da d-ribose no tratamento de arritimias cardìacas
AT08713225T ATE487485T1 (de) 2007-01-23 2008-01-23 Verwendung von d-ribose zur behandlung von vorhofflimmern
CA2674717A CA2674717C (en) 2007-01-23 2008-01-23 Use of d-ribose to treat cardiac arrhythmias
CN2008800029553A CN101588807B (zh) 2007-01-23 2008-01-23 D-核糖在制备治疗心律失常的药物中的应用
EP08713225A EP2120968B1 (en) 2007-01-23 2008-01-23 Use of d-ribose to treat atrial fibrillations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88194007P 2007-01-23 2007-01-23
US60/881,940 2007-01-23

Publications (2)

Publication Number Publication Date
WO2008091618A1 true WO2008091618A1 (en) 2008-07-31
WO2008091618A8 WO2008091618A8 (en) 2010-04-01

Family

ID=39264528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000845 Ceased WO2008091618A1 (en) 2007-01-23 2008-01-23 Use of d-ribose to treat cardiac arrhythmias

Country Status (10)

Country Link
US (1) US8101581B2 (enExample)
EP (1) EP2120968B1 (enExample)
JP (1) JP5396387B2 (enExample)
CN (1) CN101588807B (enExample)
AT (1) ATE487485T1 (enExample)
BR (1) BRPI0806231A2 (enExample)
CA (1) CA2674717C (enExample)
DE (1) DE602008003411D1 (enExample)
ES (1) ES2352154T3 (enExample)
WO (1) WO2008091618A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101581B2 (en) 2007-01-23 2012-01-24 Bioenergy, Inc. Use of D-ribose to treat cardiac arrhythmias

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
CN106138071A (zh) * 2008-04-02 2016-11-23 生物能公司 核糖在对于急性心肌梗塞的第一反应中的用途
EP3411041A1 (en) 2016-02-01 2018-12-12 RiboCor, Inc. Use of ribose for treatment of subjects having congestive heart failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
WO1994004158A1 (de) * 1992-08-25 1994-03-03 Wolfgang Pliml Verwendung von ribose zur herstellung eines arzneimittels zur behandlung von leistungsschwächen des körpers, insbesondere von organinsuffizienzen
RU2127548C1 (ru) * 1996-06-26 1999-03-20 Алабовский Владимир Владимирович Способ коронарографии в эксперименте

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605644A (en) 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4824660A (en) 1985-06-06 1989-04-25 Paul S. Angello Method of determining the viability of tissue in an organism
DE19650754A1 (de) * 1996-12-06 1998-06-10 Wolfgang Dr Pliml Ribose und Schlaganfall
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
US6218366B1 (en) 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US6429198B1 (en) 1999-04-12 2002-08-06 Bioenergy Inc. Compositions for increasing athletic performance in mammals
US20020119933A1 (en) 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6534480B2 (en) 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US6511964B2 (en) 1999-09-24 2003-01-28 Bioenergy, Inc. Method for treating acute mountain sickness
US6159943A (en) 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles
US6339716B1 (en) 1999-09-24 2002-01-15 Bioenergy Inc. Method for determining viability of a myocardial segment
US6703370B1 (en) 1999-10-27 2004-03-09 Bioenergy, Inc. Use of ribose to treat fibromyalgia
JP4927282B2 (ja) 1999-12-21 2012-05-09 バイオエナジー インコーポレイティド 血小板の保存のための組成物
CA2397707A1 (en) 2000-01-07 2001-07-19 Susan S. Percival Compositions for enhancing the immune response
US6525027B2 (en) 2000-01-20 2003-02-25 Bioenergy Inc. Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
IT1317043B1 (it) * 2000-06-14 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare potenziante il metabolismo energeticomuscolare, comprendente una alcanoil l-carnitina e ribosio.
US20030212006A1 (en) 2002-05-13 2003-11-13 Seifert John G. Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals
US8486859B2 (en) 2002-05-15 2013-07-16 Bioenergy, Inc. Use of ribose to enhance plant growth
US7687468B2 (en) 2003-05-14 2010-03-30 Viacell, LLC. Rejuvenation of stored blood
US8759315B2 (en) 2003-05-14 2014-06-24 Viacell, Llc Methods for rejuvenating
US20040229205A1 (en) 2003-05-16 2004-11-18 Ericson Daniel G. Compositions for the storage of platelets
US20090197818A1 (en) 2004-01-14 2009-08-06 St Cyr John A Use Of Ribose for Recovery From Anaesthesia
WO2005107768A2 (en) 2004-04-29 2005-11-17 Bioenergy, Inc. Method for improving ventilatory efficiency
US20100099630A1 (en) 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
PT1800675E (pt) * 2005-12-23 2011-08-30 Nutricia Nv COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA
US8835396B2 (en) 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
JP5396387B2 (ja) 2007-01-23 2014-01-22 バイオエナジー インコーポレイティド 心臓不整脈を治療するためのｄ−リボースの用途
US20090197819A1 (en) 2007-03-20 2009-08-06 Clarence Albert Johnson Compositions for improving and repairing skin
US20080312169A1 (en) 2007-03-20 2008-12-18 Clarence Albert Johnson Cosmetic use of D-ribose
US20090232750A1 (en) 2008-03-13 2009-09-17 St Cyr John A Compositions for indoor tanning
CN106138071A (zh) 2008-04-02 2016-11-23 生物能公司 核糖在对于急性心肌梗塞的第一反应中的用途
US20090286750A1 (en) 2008-05-16 2009-11-19 Kasubick Robert V Use of ribose in lessening the clinical symptoms of aberrant firing of neurons

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
WO1994004158A1 (de) * 1992-08-25 1994-03-03 Wolfgang Pliml Verwendung von ribose zur herstellung eines arzneimittels zur behandlung von leistungsschwächen des körpers, insbesondere von organinsuffizienzen
RU2127548C1 (ru) * 1996-06-26 1999-03-20 Алабовский Владимир Владимирович Способ коронарографии в эксперименте

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"RAPID COMMUNICATION. RIBOSE ACCELERATES THE REPLETION OF THE ATP POOL DURING RECOVERY FROM REVERSIBLE ISCHEMIA OF THE RAT MYOCARDIUM", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 16, no. 9, September 1984 (1984-09-01), pages 863 - 866, XP000856788, ISSN: 0022-2828 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2005, LIU, PINGHUAI ET AL: "Research of anti-myocardial ischemia and anti-arrhythmia cordis effect of D-ribose", XP002476117, retrieved from STN Database accession no. 2006:1033194 *
DATABASE WPI Week 200024, Derwent World Patents Index; AN 2000-281310, XP002476749 *
ZHONGGUO YAOYE , 14(10), 26-28 CODEN: ZYHAB5; ISSN: 1006-4931, 2005 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101581B2 (en) 2007-01-23 2012-01-24 Bioenergy, Inc. Use of D-ribose to treat cardiac arrhythmias

Also Published As

Publication number Publication date
US20080176809A1 (en) 2008-07-24
EP2120968A1 (en) 2009-11-25
ES2352154T3 (es) 2011-02-16
US8101581B2 (en) 2012-01-24
CA2674717A1 (en) 2008-07-31
WO2008091618A8 (en) 2010-04-01
ATE487485T1 (de) 2010-11-15
DE602008003411D1 (de) 2010-12-23
CA2674717C (en) 2015-10-13
BRPI0806231A2 (pt) 2011-09-06
JP2010526884A (ja) 2010-08-05
EP2120968B1 (en) 2010-11-10
JP5396387B2 (ja) 2014-01-22
CN101588807B (zh) 2012-07-04
CN101588807A (zh) 2009-11-25

Similar Documents

Publication Publication Date Title
KR20110026422A (ko) 영구적 심방 세동의 예방을 위한 드로네다론
JP2019206562A5 (enExample)
Franga et al. Recurrent asystole resulting from high cervical spinal cord injuries
Wolk et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone
CA2674717C (en) Use of d-ribose to treat cardiac arrhythmias
Sandler et al. Use of oxprenolol in cardiac arrhythmias associated with acute myocardial ischaemia
Little et al. 1988 Fitts Lecture: Heart Rate Changes after Haemorrhage and Injury—A Reappraisal
Holt et al. Intravenous amiodarone; An effective anti-arrhythmic agent
Bashour et al. Effective management of the long QT syndrome with amiodarone
Ishizuka et al. Bilateral Subclavian Vein Occlusion in a SAPHO Syndrome Patient Who Needed an Implantable Cardioverter Defibrillator An Unusual Cause of Lead Access Failure
Molajo et al. Effect of percutaneous transluminal coronary angioplasty on arrhythmias complicating angina.
Humphreys et al. Arrhythmias and their Management
Sadeghian et al. Short QT syndrome and idiopathic ventricular tachycardia in a 28-year-old young man: a potential disease-specific link?
RU2320328C2 (ru) Способ лечения персистирующей формы фибрилляции предсердий
RU2148999C1 (ru) Применение этимизола в качестве антиаритмического средства для предупреждения желудочковой экстрасистолии у больных ибс
Bayley Long-term ventricular pacing in treatment of sinoatrial block
Schober Medical treatment of tachyarrhythmias.
Noel et al. Cardiac conduction abnormalities and Stokes-Adams attacks in myotonic dystrophy
Hagens et al. Rate or rhythm control for persistent atrial fibrillation
Wright et al. Immediate effect on cardiac output of reversion to sinus rhythm from rapid arrhythmias
CN1679846A (zh) 一种治疗心脏疾病的中药
Nadamanee et al. Defibrillator vs. β-blockers for unexplained death in Thailand (DEBUT). A randomized clinical trial
Bugliosi et al. Case studies: cardiac dysrhythmias
Hitt Pacing is Beneficial in Neurally Mediated Syncope with Negative Tilt Test.
Leone et al. Amyloid deposition as a cause of atrial remodeling in persistent valvular atrial fibrillation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880002955.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08713225

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008713225

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2674717

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010517230

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0806231

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090715